Sangamo Therapeutics, Inc
SGMOQ- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001001233
No open-market purchases or sales by Sangamo Therapeutics, Inc insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $29.0K in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Sangamo Therapeutics, Inc as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 195
- +2 vs. Q4 2021
- Shares held
- 79.1M
- +2.15M (+2.8%) vs. Q4 2021
- Total value
- $459.6M
- −$117.4M (−20.3%) vs. Q4 2021
- New holders
- 30
- 57 more added
- Sold out
- 28
- 56 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SGMOQ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 6 | $29.0K |
| Q1 2026 | 112 | $26.0M |
| Q4 2025 | 105 | $26.2M |
| Q3 2025 | 112 | $42.1M |
| Q2 2025 | 114 | $39.6M |
| Q1 2025 | 122 | $34.5M |
| Q4 2024 | 128 | $62.9M |
| Q3 2024 | 103 | $48.6M |
| Q2 2024 | 129 | $31.1M |
| Q1 2024 | 131 | $68.2M |
| Q4 2023 | 130 | $47.2M |
| Q3 2023 | 135 | $61.3M |
| Q2 2023 | 152 | $137.4M |
| Q1 2023 | 180 | $197.6M |
| Q4 2022 | 182 | $326.0M |
| Q3 2022 | 197 | $477.2M |
| Q2 2022 | 188 | $371.1M |
| Q1 2022 | 195 | $459.6M |
| Q4 2021 | 193 | $577.0M |
| Q3 2021 | 193 | $679.3M |
| Q2 2021 | 197 | $912.0M |
| Q1 2021 | 203 | $994.7M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Sangamo Therapeutics, Inc; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Franklin Street Advisors Inc | 0 | $0 | 0.00% | −56,330−100.0% | Sold out |
| ClariVest Asset Management LLC | 0 | $0 | 0.00% | −50,202−100.0% | Sold out |
| Cito Capital Group, LLC | 0 | $0 | 0.00% | −44,000−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −42,900−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −38,283−100.0% | Sold out |
| Occudo Quantitative Strategies LP | 0 | $0 | 0.00% | −26,016−100.0% | Sold out |
| Diversified Trust Co | 0 | $0 | 0.00% | −22,696−100.0% | Sold out |
| Maryland Capital Management | 0 | $0 | 0.00% | −20,187−100.0% | Sold out |
| Martingale Asset Management L P | 0 | $0 | 0.00% | −19,153−100.0% | Sold out |
| United Capital Financial Advisers, LLC | 0 | $0 | 0.00% | −16,551−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −15,598−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −15,176−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −13,661−100.0% | Sold out |
| Private Advisor Group, LLC | 0 | $0 | 0.00% | −11,766−100.0% | Sold out |
| LPL Financial LLC | 0 | $0 | 0.00% | −11,498−100.0% | Sold out |
| C M Bidwell & Associates Ltd | 0 | $0 | 0.00% | −5,305−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −729−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −700−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −118−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −48−100.0% | Sold out |
| JFS Wealth Advisors, LLC | 0 | $0 | 0.00% | −4−100.0% | Sold out |
| Schubert & Co | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −46−100.0% | Sold out |